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469Coronary computed tomography angiography (CCTA) is
commonly accepted as a clinically useful modality for the diag-
nosis and exclusion of obstructive coronary artery disease
(CAD), particularly in patients with intermediate pre-test risk
(1,2). It allows for, in addition to stenosis assessment, the
noninvasive detection and further characterization of coronary
plaques even in the absence of obstruction. Although the pres-
ence of obstructive CAD is the cornerstone for further medical
and invasive therapy, multiple smaller studies (3–14) have
revealed that nonobstructive plaques might have a signiﬁcant
inﬂuence on prognosis. Nevertheless, due to the small number
of patients in these studies, only limited data exist concerning
the best parameters to describe severity and extent of coronary
atherosclerosis in the context of prognosis.See page 477
Cholesterol in Adults (Adult
Treatment Panel III)
NRI = net reclassiﬁcation
improvementThe objective of this study was to analyze the predictive
value of different parameters to assess the presence, extent,
and type of coronary atherosclerotic plaque by computed
tomography (CT) angiography and to model and validate an
optimized prognostic score for 2-year survival in a large
population of patients with suspected CAD from an inter-
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2013, accepted April 23, 2013.InteRnational Multicenter) regis-
try is an international, multicenter,
observational registry collecting
clinical, procedural, and follow-
up data of patients undergoing
CCTA for clinically indicated rea-
sons, currently comprising 31,807
patients from 17 participating sites
in 7 countries (United States,
Canada, Germany, Switzerland,
Italy, Austria, and South Korea).
The CONFIRM registry con-
tains 2 sections. Section 1 com-
prises 27,125 patients from 12
sites enrolled between January
2004 and May 2010 and was
locked in October 2010. This
section served as the test sample.
Section 2 comprises 4,682 patients from 5 sites enrolled
between July 2005 andOctober 2010 (database locked inMay
2011) and served as validation sample. Institutional review
board approval was obtained at each center.
Inclusion criteria for this analysis were: 1) patients with
suspected but not proven CAD; 2) assessment of both
luminal stenosis as well as presence and composition of
plaque in CCTA; and 3) a follow-up of at least 90 days. The
exclusion criterion of known CAD was deﬁned as patient
reported past myocardial infarction, coronary revasculariza-
tion, or presence of any stents or grafts/graft stenosis as
recorded by CT ﬁndings.
A detailed description of the methods is published else-
where (15). A structured interview was conducted before the
investigation to collect information on symptoms attributable
to cardiac disease and the presence of cardiovascular risk
factors. Systemic arterial hypertension was deﬁned as a doc-
umented history of blood pressure >140 mm Hg or treat-
ment with antihypertensive medications. Diabetes mellitus
was deﬁned by diagnosis of diabetes made previously by
a physician and/or use of insulin or oral hypoglycemic agents.
A positive smoking history was deﬁned as current smoking or
cessation of smoking within 3 months of testing. Family
history of premature coronary heart disease was deﬁned as
history of myocardial infarction of a ﬁrst-degree relative
below the age of 55 years for male and 65 years for female
relatives. In addition blood cholesterol levels of the lipid test
nearest to the index examination were recorded; the median
time interval between CT exam and lipid test was 39 days in
the test sample and 70 days in the validation sample. From
these data, the National Cholesterol Education Program
Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel
III) (NCEP ATP III) score (16), the Framingham risk score
(17), and the Morise clinical risk score (18) were calculated.
Image acquisition and analysis. All CCTA investigations
were performed on multiple-row detector CT scanners with
at least 64 simultaneously acquired slices, and the imaging
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470protocol adhered to the Society of Cardiovascular Com-
puted Tomography guidelines on appropriateness and per-
formance of CCTA, as far as available at the time of
scanning (2,19,20). Patient preparation, data acquisition,
and analysis were according to the institutional policies of
the local sites.
Coronary segments were scored visually for the presence
and composition of coronary plaque and degree of luminal
stenosis with a 16-segment coronary artery model (21). In
each coronary artery segment, plaques were classiﬁed as
noncalciﬁed, mixed, or calciﬁed. The presence of coronary
calciﬁcation was determined visually in the contrast-
enhanced dataset. Noncalciﬁed plaque was deﬁned as
a tissue structure >1 mm2 that could be clearly discriminated
from the vessel lumen and surrounding tissue, with a density
below the contrast-enhanced blood pool. Plaques meeting
this deﬁnition and in addition showing calciﬁed areas of any
extent were classiﬁed as mixed plaques. The severity of
luminal diameter stenosis was scored visually as none (0%
luminal stenosis), mild (1% to 49% luminal stenosis),
moderate (50% to 69% luminal stenosis), or severe (70%
luminal stenosis). For further analysis, the numbers of
segments with a speciﬁc plaque composition or a speciﬁc
luminal stenosis were summed up. The number of segments
with any plaque or stenosis is equivalent to the segment
involvement score proposed by Min et al. (7).
From each of these base scores optimized jeopardy scores
were derived, assessing only proximal segments (proximal and
mid right coronary artery, left main, proximal, and mid
left anterior descendent, proximal circumﬂex, ﬁrst obtuse
marginal branch) and describing the result in 3 categories: no
proximal segment affected; 1 proximal segment affected; 2
proximal segments affected.
With the best clinical risk score and the most predictive
CCTA parameters the combined CONFIRM risk score was
modeled.
Follow-up and study endpoint. The primary endpoint of
the study was time to death from any cause. In U.S. sites,
death status was ascertained by querying the Social Security
Death Index. In non-U.S. sites, follow-up data were
collected by mail or telephone contact with the patients or
their families; events were veriﬁed by hospital records or
contacts with the attending physician.
Statistical analysis. Categorical variables were expressed as
frequencies and percentages; continuous variables were ex-
pressed as mean  SD. All statistical evaluations are
based on survival with the Kaplan-Meier method; hazard
ratios (for difference between 75th and 25th percentile)
and multivariable analyses were calculated with the Cox
proportional hazard model. Signiﬁcant contribution to a
multivariable model was tested with Akaike’s information
criterion. C-indexes were calculated from time-to-event data
as proposed by Harrell et al. (22). The incremental predictive
value was assessed with the net reclassiﬁcation improvement
(NRI) according to Pencina et al. (23). For modeling the
CONFIRM risk score, both internal validation by randomlysplitting the test sample and external validation on an inde-
pendent dataset were performed; the modeling process is
described in detail in a statistical supplement in the Online
Appendix. Statistical signiﬁcance was accepted for 2-sided
p values <0.05. The statistical package R (version 2.10.1)
(24) including the package rms (25) was used for statistical
analysis.Results
Study population, clinical characteristics, and follow-up.
Of 27,125 patients in the test sample, 2,350 patients were
excluded because of known CAD, 814 patients were
excluded because of missing data on contrast enhanced
coronary angiography (mainly because only calcium scoring
was performed), 5,844 patients were excluded from sites not
assessing plaque characterization, 1 patient was excluded
because of missing information on age, and 323 patients
were excluded because available follow-up was missing
or <90 days. Hence, the study population for the test sample
comprised 17,793 patients. Of 4,682 patients in the vali-
dation sample, 377 patients were excluded because of known
CAD, 447 patients were excluded because of missing data
on contrast enhanced coronary angiography, 1,334 patients
were excluded from sites not assessing plaque characteriza-
tion, 5 patients were excluded because of missing informa-
tion on age, and 13 patients were excluded because available
follow-up was missing or <90 days. Hence, the study
population for the test sample comprised 2,506 patients.
Median age of the patients was 58 years (interquartile
range [IQR]: 49 to 66 years) in the test sample and 57 years
[IQR: 48 to 65 years] in the validation sample (p < 0.0001).
Sex distribution was similar in both groups, with 9,440 men
(53%) in the test sample, and 1,319 men (53%) in the vali-
dation sample (p ¼ 0.70). There were signiﬁcant differences
in risk proﬁle and symptoms on presentation, as can be seen
in Table 1. The pre-test risk was predominantly low when
assessed by the NCEP ATP III and Framingham score and
predominantly intermediate, according to the Morise score.
During a median follow-up of 2.3 years (IQR: 1.6 to 3.1
years) in the test sample, 317 patients died. This corresponds
to an annual mortality rate of 0.75% (95% conﬁdence
interval [CI]: 0.67% to 0.82%). In the validation sample the
median follow-up was 1.5 years (IQR: 1.0 to 2.8 years), and
30 patients died, resulting in an annual mortality rate of
0.63% (95% CI: 0.45% to 0.91%).
Predictive value of clinical risk scores. All 3 clinical risk
scores correlated signiﬁcantly with outcome. The best was
NCEP ATP III (c-index 0.706), followed by the Fra-
mingham risk (c-index 0.623) and then the Morise (c-index
0.618) scores (see also Table 2). The difference between
NCEP ATP III and Framingham was signiﬁcant (p <
0.0001); therefore all further analysis was based on NCEP
ATP III.
Predictive value of CCTA. Patients had 2.1  2.8 coro-
nary segments affected by plaques, of which 0.3  0.9 (17%)
Table 1 Clinical Characteristics and Risk Factors
Test Sample
(n ¼ 17,793)
Validation Sample
(n ¼ 2,506) p Value
Age, yrs 58 (49–66) 57 (48–65) <0.0001
Male 9,440 (53%) 1,319 (53%) 0.70
Hypertension 9,029 (51%) 1,432 (57%) <0.0001
Diabetes 2,668 (15%) 402 (16%) 0.17
Total cholesterol, mg/dl 189 (162–217) 196 (166–226) <0.0001
LDL cholesterol, mg/dl 115 (92–140) 114 (89–141) 0.36
HDL cholesterol, mg/dl 51 (42–61) 52 (43–64) 0.0003
Current smoker 3,634 (20%) 471 (19%) 0.059
Family history for CAD 6,174 (35%) 1,136 (45%) <0.0001
Angina pectoris <0.0001
Nonanginal chest pain 2,316 (13%) 390 (16%)
Atypical angina 6,491 (37%) 476 (19%)
Typical angina 3,024 (17%) 553 (22%)
Dyspnea on exertion 5,919 (33%) 569 (23%) <0.0001
NCEP ATP III risk 7.5 (2.5–16.4) 6.4 (2.0–16.6) 0.0013
Low risk (<10) 10,522 (59%) 1,523 (61%)
Intermediate risk (10–20) 3,551 (20%) 433 (17%)
High risk (>20) 3,720 (21%) 550 (22%)
Framingham risk 9.8 (5.9–15.9) 9.8 (5.7–16.1) 0.49
Low risk (<10) 9,022 (51%) 1,263 (51%)
Intermediate risk (10–20) 5,637 (32%) 790 (32%)
High risk (>20) 2,951 (17%) 430 (17%)
Morise score 11 (9–14) 11 (9–13) 0.015
Low risk (<9) 3,510 (20%) 486 (19%)
Intermediate risk (9–15) 12,445 (70%) 1,794 (72%)
High risk (>9) 1,838 (10%) 226 (9%)
Values are median (interquartile range) or occurrences (%).
CAD ¼ coronary artery disease; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; NCEP ATP III ¼ National Cholesterol Education
Program Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
JACC Vol. 62, No. 5, 2013 Hadamitzky et al.
July 30, 2013:468–76 Optimized Prognostic Score for Coronary CTA
471were noncalciﬁed, 0.8  1.6 (38%) were mixed, and 0.9 
1.7 (45%) were calciﬁed. A mean of 0.5  1.1 segments
(22% of all segments with plaques) revealed a signiﬁcant
stenosis (>50% lumen reduction), and 0.2  0.6 (7%)
revealed a severe stenosis (>70% lumen reduction).
All of these parameters correlated signiﬁcantly with
outcome, except the number of segments with noncalciﬁed
plaques. After correction for clinical risk, the correlationTable 2 Predictive Value of Clinical Risk Scores in the Test Group
Score
No Death
(n ¼ 17,476)
Death
(n ¼ 317)
NCEP ATP III risk 9.4  7.7 15.5  8.2
Low risk (<10) 10,437 (60%) 85 (27%)
Intermediate risk (10–20) 3,460 (20%) 91 (29%)
High risk (>20) 3,579 (20%) 141 (44%)
Framingham risk 12.5  9.97 19.9  16.6
Low risk (<10) 8,920 (52%) 104 (33%)
Intermediate risk (10–20) 5,543 (32%) 94 (30%)
High risk (>20) 2,832 (16%) 119 (37%)
Morise score 11.3  3.25 12.7  2.84
Low risk (<9) 3,492 (20%) 18 (6%)
Intermediate risk (9–15) 12,203 (70%) 242 (76%)
High risk (>9) 1,781 (10%) 57 (18%)
Values are mean  SD or n (%), unless otherwise indicated.
CI ¼ conﬁdence interval.with outcome remained signiﬁcant only for the total number
of segments with plaque (c-index 0.62, p < 0.0001). The
predictive value could be signiﬁcantly increased by focusing
on proximal segments only (p ¼ 0.0026 compared with the
total number of segments with plaque) and further by only
counting calciﬁed or mixed plaque (p ¼ 0.0030 for
improvement). Although the number of all segments with
stenosis >50% did not correlate signiﬁcantly with outcome,Hazard Ratio
(95% CI) Chi-Square C-Index p Value
3.01 (2.62–3.45) 171 0.706 <0.001
1.54 (1.44–1.65) 118 0.623 <0.001
1.98 (1.67–2.36) 60 0.618 <0.001
Table 3 Predictive Value of Degree of Stenosis and Plaque Composition
CT Parameter
No Death
(n ¼ 17,476)
Death
(n ¼ 317)
Hazard Ratio
(95% CI)
Uncorrected Corrected for Clinical Risk
C-Index p Value C-Index p Value
Number of segments with any plaque or stenosis 2.1  2.7 3.6  2.87 1.22 (1.03–1.44) 0.683 <0.0001 0.621 <0.0001
Number of segments with stenosis >50% 0.45  1.06 1.1  1.58 1.17 (1.05–1.29) 0.643 <0.0001 0.524 0.29
Number of segments with stenosis >70% 0.15  0.56 0.46  0.99 1.26 (1.07–1.48) 0.603 <0.0001 0.535 0.18
Number of segments with noncalciﬁed plaques 0.4  0.86 0.31  0.64 1.00 (0.84–1.19) 0.502 0.9 0.501 0.99
Number of segments with mixed plaques 0.77  1.62 1.52  1.9 1.06 (0.98–1.15) 0.619 <0.0001 0.516 0.60
Number of segments with calciﬁed plaques 0.92  1.72 1.77  2.4 1.08 (1.01–1.15) 0.642 <0.0001 0.550 0.10
Number of segments with calciﬁed or mixed plaques 1.69  2.44 3.28  2.68 1.41 (1.21–1.65) 0.696 <0.0001 0.618 <0.0001
Number of proximal segments with calciﬁed or
mixed plaques
0.32  0.65 0.77  0.87 1.39 (1.14–1.70) 0.696 <0.0001 0.643 <0.0001
Number of proximal segments with stenosis >50% 0.14  0.43 0.41  0.67 1.46 (1.15–1.87) 0.652 <0.0001 0.563 0.04
Values are mean  SD, unless otherwise indicated.
CI ¼ conﬁdence interval; CT ¼ computed tomography.
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472the number of proximal segments with stenosis >50% was
a signiﬁcant predictor (c-index 0.56, p ¼ 0.003). Adjusted
risk stratiﬁcation is summarized in Table 3 and graphically
displayed in Figure 1. Compared with NCEP ATP III score
(c-index 0.706) risk prediction could be improved both by
the number of proximal segments with mixed or calciﬁed
plaques (c-index 0.741 for the combined model, p < 0.0001
for improvement) and the number of proximal segments
with stenosis >50% (c-index 0.734 for the combined model,
p ¼ 0.003 for improvement).
Combined score. An optimized score was modeled, com-
bining clinical risk assessment and CCTA parameters that
comprised 3 parameters: the NCEP ATP III score, the num-
ber of proximal segments with stenosis>50%, and the number
of proximal segments with either calciﬁed or mixed plaques.
This model could signiﬁcantly improve prediction beyond
the NCEP ATP III score both in the test sample (NRI 49%,Figure 1 Kaplan-Meier Plot
Survival probability dependent on proximal segments with calciﬁed or mixed plaque (left)
Education Program Expert Panel on Detection, Evaluation, And Treatment of High Blood Cp < 0.0001) and in the validation sample (NRI 60%, p ¼
0.0011). The model is summarized in Table 4, the incremen-
tal predictive value is visualized in Figure 2, and a detailed
description of the modeling process is provided as a statistical
supplement in the Online Appendix. An online calculator
for the CONFIRM prognostic score is available (26).
To be comparable with the NCEP APT III score, which
assesses the risk for cardiac death or myocardial infarction
instead of overall mortality as used in this study, cutoffs of
0.8% and 1.6% annual mortality rate between low and
intermediate risk and between intermediate and high risk
were used, respectively. With these values, the annual
mortality rate ranged from 0.32% (95% CI: 0.26% to
0.39%) for low risk to 1.3% (95% CI: 1.1% to 1.6%) for
intermediate risk to 2.4% (95% CI: 2.0% to 2.9%) for high
risk in the test sample and from 0.29% (95% CI: 0.15% to
0.56%) for low risk to 1.1% (95% CI: 0.64% to 2.0%) forand proximal stenosis >50% (right), corrected for National Cholesterol
holesterol In Adults (Adult Treatment Panel III) score.
Table 4 Incremental Predictive Value of Proximal Plaque in CCTA
Model Net Reclassiﬁcation From Clinical Risk
Parameter Coefﬁcient p Value Test Sample Validation Sample
Model 1: Clinical risk Base model Base model
NCEP ATP III risk 0.207 <0.0001
Model 2: Clinical risk þ CT parameters 49% (p < 0.0001) 60% (p ¼ 0.0011)
NCEP ATP III risk 0.144 <0.0001
Proximal mixed or calciﬁed plaque 0.407 0.0003
Proximal stenosis >50% 0.398 0.0001
National Cholesterol Education Program Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult
Treatment Panel III) (NCEP ATP III) risk is formatted to represent 1 score point in the published point system. The ﬁrst 2 proximal segments with
calciﬁed or mixed plaques and the ﬁrst 2 proximal segments with a stenosis >50% are each equivalent to 2.8 points (16). For further details
please refer to the statistical supplement in the Online Appendix.
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473intermediate risk to 1.6% (95% CI: 0.84% to 3.1%) for
high risk in the validation sample. With these risk cate-
gories, 32% of the patients in the test sample and 33% of
the patients in the validation sample could be reclassiﬁed
with regard to their cardiovascular risk. In the test sample
3,909 patients (22.0%) were assigned to a lower risk, and
1,774 patients (10.0%) were assigned to a higher risk.
Similar percentages were found in the validation sample, as
described in Figure 3 in more detail.
Discussion
It is well known from single-center studies that, in addition to
the degree of stenosis, the extent of coronary atherosclerosis as
documented by CCTA is an important prognostic factor.
Ostrom et al. (10) demonstrated a correlation betweenmortality
and the number of involved vessels both for nonobstructive
and obstructive lesions. Min et al. (7) found that a segment
involvement score counting segments that exhibited plaque,
irrespective of stenosis severity, had a particularly good correla-
tion with survival. Our analysis of 20,299 patients from the
international CONFIRM registry reafﬁrms the predictive valueFigure 2 ROC Curve for All-Cause Mortality
Receiver operator characteristics (ROC) of Morise; Framingham; and National Cholesterol E
Cholesterol In Adults (Adult Treatment Panel III) (NCEP ATP III) clinical scores and the opti
and proximal segments with stenosis >50%). Test sample on the left, and validation sa
Outcomes: An InteRnational Multicenter registry.of segmental plaque burden above and beyond the degree of
stenosis.
Multiple studies both on invasive angiography and on
CCTA have shown that diseased proximal segments are
prognostically more relevant than distal ones, and a number of
jeopardy scores with varying complexity have been proposed to
account for this fact (7,27,28). In our patient population, we
identiﬁed 7 coronary segments as being important for prog-
nosis: the left main, proximal, mid-left anterior descending,
proximal circumﬂex and the ﬁrst obtuse marginal branch, and
the proximal and mid-right coronary artery. By focusing only
on the presence of atherosclerotic plaques in these segments
the predictive value of CCTA could be improved signiﬁcantly.
With regard to plaque composition, we found that
exclusively noncalciﬁed plaques had no signiﬁcant correla-
tion with mortality. Furthermore, a predictive model
considering only mixed or calciﬁed plaques was signiﬁcantly
better than a model considering all plaques. This result is
surprising, because non-calciﬁed plaque components are
often considered more vulnerable to future rupture and
hence future myocardial infarction and death (29,30). A
possible explanation for this ﬁnding could be that CCTA isducation Program Expert Panel on Detection, Evaluation, And Treatment of High Blood
mized score (additionally including proximal segments with calciﬁed or mixed plaque
mple on the right. CONFIRM ¼ COronary CT Angiography EvaluatioN For Clinical
Figure 3 Reclassiﬁcation of Risk Prediction
Reclassiﬁcation matrix between NCEP ATP III and optimized score for all patients in the test (ﬁrst) and validation sample (second) and separated by outcome (death [third],
no death [fourth], test sample only). Abbreviations as in Figure 2.
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vulnerable plaques are only a small fraction of all noncalciﬁed
plaques identiﬁed by CCTA. Taking into account the size of
this study population, this ﬁnding deserves further analysis
beyond the scope of the present report.
On the basis of the current study, we identiﬁed the
2 parameters “number of proximal segments with mixed orcalciﬁed plaques” and “number of proximal segments with
stenosis >50%” as the best CCTA parameter improving
outcome predicting beyond clinical risk scores.
Putting these parameters in context with the clinical risk
factors as assessed by the NCEP ATP III score, which was
the best clinical risk predictor in our cohort, we found that
both a proximal segment with mixed or calciﬁed plaques and
JACC Vol. 62, No. 5, 2013 Hadamitzky et al.
July 30, 2013:468–76 Optimized Prognostic Score for Coronary CTA
475a proximal segment with stenosis >50% are equivalent to 2.8
score points in the published point model of the NCEP
ATP III score (16), which is in the same range as an increase
in age of 5 years or the average risk of smoking.
These results conﬁrm the incremental prognostic value of
CCTA beyond clinical risk factors and allow for a quantiﬁ-
cation of the risk associated with proximal plaque in CCTA.
This risk is not only signiﬁcant but also substantial and in
the same ranges as relevant clinical risk factors like hyper-
tension or smoking. Thus CCTA can describe the vascular
age and the associated risk for mortality.
Assessing the prognosis of a typical patient undergoing
CCTA having a low to intermediate risk for CAD is difﬁcult.
Most of the established risk scores like the Framingham risk
score are tested on asymptomatic individuals and aim for the
long-term prediction of symptomatic CAD. Both criteria are
not met in the patient group of interest. Even the Morise
score, which is designed for the risk of all-cause mortality
in symptomatic patients, had a limited predictive value in
our study population. Obviously, this score, which was vali-
dated on a patient population with a higher annual mortality
(1.1% vs. 0.75% in our study), cannot be applied to a low- to
intermediate-risk population without restrictions.
It is our opinion, on the basis of the largest patient pop-
ulation currently available, that the proposed combined score
now clearly improves risk prediction beyond established
clinical risk scores and allows for a robust risk assessment of
patients with suspected CAD undergoing CCTA.
This might facilitate a more targeted prevention regimen
for CAD. Patients at high risk according to the new score
have an annual mortality risk of >1.0%, and an intensiﬁed
preventive regimen including both lifestyle change and
medication seems logical. In low-risk patients, there might
be the possibility for reducing preventive efforts. However,
we have limited information on medication during follow-
up in our study, and this option must be validated by
prospective outcome studies.
An analysis of invasive angiographies and revasculariza-
tions during follow-up is beyond the scope of this study and
is covered by a companion paper (31).
Study limitations. This is an observational multicenter
study. Pre-test risk differs signiﬁcantly between sites. This
might confound the results of the study. However, the risk
score performed signiﬁcantly in all sites (Online Appendix),
demonstrating the broad applicability of the results. There is
only limited information with regard to lifestyle modiﬁcation
and medical and interventional therapy during follow-up, so
that a correction for its confounding inﬂuence was not
possible. This is an inherent limitation of the study design and
can only be circumvented by prospective outcome trials.
Nevertheless, the results of this study are based on the largest
currently available pooled patient population, and they can
serve as a robust base for the design and initiation of such
trials.
The weak correlation between noncalciﬁed plaques and
outcome might be caused by the heterogeneity of the studypopulation and the equipment used. Detection of noncalciﬁed
plaques is not always easy, particularly with suboptimal image
quality, and might be inﬂuenced by ﬁlters used for image
presentation, which vary considerably between vendors. In
addition, advanced reconstruction algorithms were not widely
available at the time the scans of this study were performed.
Conclusions
In patients undergoing CCTA, both atherosclerotic plaque
burden and obstructive coronary diseasedparticularly in the
proximal segmentsdcarry incremental prognostic value
beyond clinical risk factors. The increase in mortality risk
associated with the presence of proximal CAD manifesta-
tion in CCTA is comparable with the risk of clinical risk
factors like smoking or an increase in “vascular” age of 5
years. A predictive score combining CCTA parameters with
clinical information signiﬁcantly improves prediction
compared with well-established clinical risk scores and
allows for a reclassiﬁcation of approximately one-third of the
patients with regard to their mortality risk.
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